A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
This study aims to find out if the proposed study drug, OM-85, a marketed product in several countries worldwide but not in the US yet, helps make children’s recurrent wheezing better than other drugs or other types of treatments that are currently available and approved in the US market.
Sponsor: OM Pharma SA
NCT05857930 - IRB#2023-065